中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国医疗保健国际交流促进会免疫学分会, 《靶免联合局部治疗中晚期肝细胞癌中国专家共识》协作组. 靶向免疫联合局部治疗中晚期肝细胞癌中国专家共识[J]. 肝癌电子杂志, 2023, 10(3): 1-11.
| [1] FINN R S, QIN S, IKEDA M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. [2] REN Z, XU J, BAI Y, et al.Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. [3] QIN S, CHAN S L, GU S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study [J]. Lancet, 2023. In press. [4] ZHU H D, LI H L, HUANG M S, et al.Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)[J]. Signal Transduct Target Ther, 2023, 8(1): 58. [5] HE M K, LIANG R B, ZHAO Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Adv Med Oncol, 2021, 13: 17588359211002720. [6] LIU D, MU H, LIU C, et al.Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial[J]. J Clin Oncol, 2022, 40(16 Suppl): 4073. [7] GU Y K, ZHANG T Q, ZUO M X, et al.Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: a prospective, single-arm, phase II trial (TRIPLET study)[J]. J Clin Oncol, 2022, 40(16 Suppl): 4106. [8] ZANG M, PANG H, LI C, et al.Camrelizumab combined with lenvatinib and RALOX-HAICfor hepatocellular carcinoma (HCC) in BCLC stage B and C: a prospective, single-arm, phase II trial (Cal Era study)[J]. J Clin Oncol, 2023, 41(16 Suppl): e16128. [9] ZHANG X Y, ZHU X, FENG X, et al.715P The safety and efficacy of lenvatinib combined withTACEand PD-1 inhibitors (Len-TAP) versusTACEalone in the conversion resection for initially unresectable hepatocellular carcinoma: interim results from a multicenter prospective cohort study[J]. Ann Oncol, 2022, 33: S870. [10] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022,42(3):241-273. [11] 中国医师协会介入医师分会临床诊疗指南专委会,滕皋军,赵明等.中国肝癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版)[J]. 中华内科杂志,2021,60(7):599-614. [12] LLOVET J M, DE BAERE T, KULIK L, et al.Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(5): 293-313. [13] KUDO M, HAN G, FINN R S, et al.Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase Ⅲ trial[J]. Hepatology, 2014, 60(5): 1697-1707. [14] KUDO M, CHENG A L, PARK J W, et al.Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study[J]. Lancet Gastroenterol Hepatol, 2018, 3(1): 37-46. [15] GOLFIERI R, GIAMPALMA E, RENZULLI M, et al.Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. Br J Cancer, 2014, 111(2): 255-264. [16] HAN Z, YANG F, ZHANG Y, et al.Prognostic efficacy and prognostic factors ofTACEplus TKI with ICIsfor the treatment of unresectable hepatocellular carcinoma: a retrospective study[J]. Front Oncol, 2022, 12: 1029951. [17] WANG W J, LIU Z H, WANG K, et al.Efficacy and safety ofTACEcombined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study[J]. Cancer Med, 2023, 12(10): 11513-11524. [18] YANG X G, SUN Y Y, WANG H Q, et al.Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: a propensity score matching analysis[J]. Front Oncol, 2022, 12: 914385. [19] LLOVET J M, VOGEL A, MADOFF D C, et al.Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment[J]. Cardiovasc Intervent Radiol, 2022, 45(4): 405-412. [20] 古善智, 谭玉林, 胡鸿涛, 等. 甲苯磺酸多纳非尼片、抗PD-1单抗联合经动脉化疗栓塞治疗(TACE)用于不可切除的肝癌(uHCC) [C]. 南京:2022年CSCO学术论文汇编, 肝胆胰肿瘤口头报告: 24-25. [21] 曹亚娟, 张雪斌, 史炯, 等. 甲苯磺酸多纳非尼联合经肝动脉栓塞化疗(TACE)及卡瑞利珠单抗转化治疗初始不可切除的肝细胞癌:一项前瞻性、单臂、单中心Ⅱ期临床试验[J].临床肿瘤学杂志,2023,28(6):481-487. [22] 中国抗癌协会肿瘤介入学专业委员会, 中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会. 改良式经皮肝动脉化疗药盒植入技术中国专家共识(2022版)[J]. 临床肝胆病杂志, 2022, 38(11): 633-641. [23] ZHENG K, ZHU X, FU S, et al.Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial[J]. Radiology, 2022, 303(2): 455-464. [24] HE M, LI Q, ZOU R, et al.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. [25] LAI Z, HE M, BU X, et al.Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, phase II trial[J]. Eur J Cancer, 2022, 174: 68-77. [26] GAO W, LIU C, LI G, et al.Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): a prospective, single-arm phase II trial (DoHAICs study)[J]. J Clin Oncol, 2023, 41(16 Suppl): e16165. [27] CHENG A L, QIN S, IKEDA M, et al.Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76(4): 862-873. [28] REIG M, FORNER A, RIMOLA J, et al.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76(3): 681-693. [29] LEE Y H, TAI D, YIP C, et al.Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond[J]. Front Immunol, 2020, 11: 568759. [30] LUKE J J, LEMONS J M, KARRISON T G, et al.Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors[J]. J Clin Oncol, 2018, 36(16): 1611-1618. [31] CHIANG C L, CHAN A C Y, CHIU K W H, et al. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy[J]. Front Oncol, 2019, 9: 1157. [32] CHEN Y, HONG H, FANG W, et al.Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study[J]. Front Oncol, 2023, 13: 1113389. [33] LI J X, SU T S, GONG W F, et al.Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial[J]. Hepatol Int, 2022, 16(5): 1179-1187. [34] QIU H, KE S, CAI G, et al.An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma[J]. Cancer Med, 2023, 12(1): 213-222. [35] CHEN B, LI Y X, WANG L, et al.Phase II study of concurrent sorafenib and radiotherapy for advanced hepatocellular carcinoma with portal vein and/or hepatic vein tumor thrombosis[J]. Int J Radiat Oncol Biol Phys, 2021, 111(3 Suppl): S39. [36] NING C, ZHANG X, WANG Y, et al. Radiotherapy with combination therapy of immune checkpoint inhibitors and anti-angiogenic therapy for hepatocellular carcinoma [J]. Int J Radiat Oncol Biol Phys, 2023. In press. [37] NING C, JIA J, ZHANG X, et al. Efficacy and safety of subsequent radiotherapy in patients with advanced-stage hepatocellular carcinoma treated with immune checkpoint inhibitors. [J]. Hepatobiliary Surg Nutr, 2023. In press. [38] FAN J, TANG Z Y, YU Y Q, et al.Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma[J]. Dig Surg, 1998, 15(6): 674-678. [39] TANG Z Y, UY Y Q, ZHOU X D, et al.Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients[J]. World J Surg, 1995, 19(6): 784-789. [40] 赵海涛, 桑新亭, 芮静安, 等. 不能手术切除的晚期肝癌降期后切除疗效分析[J]. 中国医学科学院学报, 2009, 31(4): 503-505. [41] 陈亚进. 肝癌转化治疗现状与思考[J]. 中国实用外科杂志, 2021, 41(3): 253-256,261. [42] KUBOTA K, AOKI T, KUMAMARU H, et al.Use of the National Clinical Database to evaluate the association between preoperative liver function and postoperative complications among patients undergoing hepatectomy[J]. J Hepatobiliary Pancreat Sci, 2019, 26(8): 331-340. [43] IMAMURA H, SEYAMA Y, KOKUDO N, et al.One thousand fifty-six hepatectomies without mortality in 8 years[J]. Arch Surg, 2003, 138(11): 1198-1206. [44] 袁声贤, 周伟平. 原发性肝癌转化治疗的进展和体会[J]. 肝胆外科杂志, 2022,30(3):161-164,168. [45] PAYE F, JAGOT P, VILGRAIN V, et al.Preoperative chemoembolization of hepatocellular carcinoma: a comparative study[J]. Arch Surg, 1998, 133(7): 767-772. [46] YANG J, TAO H S, CAI W, et al.Accuracy of actual resected liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging[J]. J Surg Oncol, 2018, 118(7): 1081-1087. [47] MISE Y, HASEGAWA K, SATOU S, et al.How has virtual hepatectomy changed the practice of liver surgery?: experience of 1194 virtual hepatectomy before liver resection and living donor liver transplantation[J]. Ann Surg, 2018, 268(1): 127-133. [48] GRUTTADAURIA S, VASTA F, MINERVINI M I, et al.Significance of the effective remnant liver volume in major hepatectomies[J]. Am Surg, 2005, 71(3): 235-240. [49] XIONG J J, ALTAF K, JAVED M A, et al.Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma[J]. World J Gastroenterol, 2012, 18(45): 6657-6668. [50] FU B, ZHANG J R, HAN P S, et al.Comparison of survival and post-operation outcomes for minimally invasive versus open hepatectomy in hepatocellular carcinoma: A systematic review and meta-analysis of case-matched studies[J]. Front Oncol, 2022, 12: 1021804. [51] 中国抗癌协会肝癌专业委员会转化治疗协作组, 樊嘉, 秦叔逵, 等. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6): 618-632. [52] OMATA M, CHENG A L, KOKUDO N, et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370. [53] EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. [54] CHEN M S, LI J Q, ZHENG Y, et al.A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]. Ann Surg, 2006, 243(3): 321-328. [55] KUDO M, HASEGAWA K, KAWAGUCHI Y, et al.A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival[J]. J Clin Oncol, 2021, 39(15 Suppl): 4093. [56] LI L, ZHANG J, LIU X, et al.Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(1): 51-58. [57] CHO Y K, KIM J K, KIM M Y, et al.Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies[J]. Hepatology, 2009, 49(2): 453-459. [58] WEINSTEIN J L, AHMED M.Percutaneous ablation for hepatocellular carcinoma[J]. AJR Am J Roentgenol, 2018, 210(6): 1368-1375. [59] PENG Z W, ZHANG Y J, CHEN M S, et al.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial[J]. J Clin Oncol, 2013, 31(4): 426-432. [60] NAULT J C, SUTTER O, NAHON P, et al.Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations[J]. J Hepatol, 2018, 68(4): 783-797. [61] CHENG P L, WU P H, KAO W Y, et al.Comparison of local ablative therapies, including radiofrequency ablation, microwave ablation, stereotactic ablative radiotherapy, and particle radiotherapy, for inoperable hepatocellular carcinoma: a systematic review and meta-analysis[J]. Exp Hematol Oncol, 2023, 12(1): 37. [62] AHMED M, SOLBIATI L, BRACE C L, et al.Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update[J]. Radiology, 2014, 273(1): 241-260. [63] GLAZER D I, TATLI S, SHYN P B, et al.Percutaneous image-guided cryoablation of hepatic tumors: single-center experience with intermediate to long-term outcomes[J]. AJR Am J Roentgenol, 2017, 209(6): 1381-1389. [64] LEE E W, WONG D, PRIKHODKO S V, et al.Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes[J]. J Vasc Interv Radiol, 2012, 23(1): 107-113. [65] KUMAR M, PANDA D.Role of Supportive care for terminal stage hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2014, 4(Suupl 3): S130-S139. [66] HAMMAD A Y, ROBBINS J R, TURAGA K K, et al.Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database[J]. Ann Palliat Med, 2016, 6(1): 26-35. [67] 成远, 华海清. 榄香烯治疗原发性肝癌的研究进展[J]. 临床肿瘤学杂志, 2017, 22(10): 950-953. [68] 路大鹏, 王玉强, 赵卫林, 等. 康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究[J]. 世界临床医学, 2017, 11(5): 70. [69] 田怀平, 高蕙敏, 杨萍, 等. 华蟾素联合肝动脉化疗栓塞治疗原发性肝癌的疗效与安全性Meta分析[J]. 世界中医药, 2016, (10): 2151-2155. [70] 陈乃杰, 金源, 赖义勤, 等. 消癌平联合化疗治疗中晚期肝癌22例[J]. 中医杂志, 2005, 46(6): 444-445. [71] 童光武, 高鹏. 消癌平注射液联合榄香烯注射液治疗中晚期原发性肝癌的临床研究[J]. 现代药物与临床, 2016,31(5):691-695 [72] 刘冬梅. 肝复乐胶囊联合肝动脉栓塞化疗治疗晚期肝癌的疗效观察 [J/CD]. 临床医药文献电子杂志, 2016, 3(2): 235-236. [73] 杨玉雪, 何璇, 文建霞, 等. 艾迪注射液与肝动脉栓塞化疗联合治疗原发性肝癌的系统评价[J]. 中国医院用药评价与分析, 2016, 16(12): 1588-1593. [74] SUN Y, QIN S, LI W, et al.A randomized, double-blinded, phase Ⅲ study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: Interim analysis result[J]. J Clin Oncol, 2021, 39(15 Suppl): 4077. [75] BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66. [76] ZHU A X, FINN R S, EDELINE J, et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. [77] FINN R S, RYOO B Y, MERLE P, et al.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase Ⅲ Trial[J]. J Clin Oncol, 2020, 38(3): 193-202. [78] QIN S, CHEN Z, FANG W, et al.Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study[J]. J Clin Oncol, 2022, 40(4 Suppl): 383. [79] QIN S, LI Q, GU S, et al.Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 559-568. [80] ZHU A X, KANG Y K, YEN C J, et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296. [81] KUDO M, FINN R S, QIN S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. [82] IKEDA M, KOBAYASHI M, TAHARA M, et al.Optimal management of patients with hepatocellular carcinoma treated with lenvatinib[J]. Expert Opin Drug Saf, 2018, 17(11): 1095-1105. [83] POSTOW M A, SIDLOW R, HELLMANN M D.Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. [84] THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al.NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(3): 230-241. [85] BARROSO-SOUSA R, BARRY W T, GARRIDO-CASTRO A C, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and Meta-analysis[J]. JAMA Oncol, 2018, 4(2): 173-182. [86] GEUKES-FOPPEN M H, ROZEMAN E A, VAN WILPE S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management[J]. ESMO Open, 2018, 3(1): e000278. [87] DELANOY N, MICHOT J M, COMONT T, et al.Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study[J]. Lancet Haematol, 2019, 6(1): e48-e57. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
